Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

181 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082.
Marks LB, Cirrincione C, Fitzgerald TJ, Laurie F, Glicksman AS, Vredenburgh J, Prosnitz LR, Shpall EJ, Crump M, Richardson PG, Schuster MW, Ma J, Peterson BL, Norton L, Seagren S, Henderson IC, Hurd DD, Peters WP; Cancer and Leukemia Group B; Southwest Oncology Group; National Cancer Institute of Canada Clinical Trials Group. Marks LB, et al. Among authors: henderson ic. Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1305-13. doi: 10.1016/j.ijrobp.2009.04.013. Epub 2009 Sep 9. Int J Radiat Oncol Biol Phys. 2010. PMID: 19747781 Free PMC article. Clinical Trial.
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson IC, Citron ML, Norton L, Winer EP, Hudis CA; Cancer and Leukemia Group B Experience. Muss HB, et al. Among authors: henderson ic. J Clin Oncol. 2007 Aug 20;25(24):3699-704. doi: 10.1200/JCO.2007.10.9710. J Clin Oncol. 2007. PMID: 17704418 Clinical Trial.
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
Peters WP, Rosner GL, Vredenburgh JJ, Shpall EJ, Crump M, Richardson PG, Schuster MW, Marks LB, Cirrincione C, Norton L, Henderson IC, Schilsky RL, Hurd DD. Peters WP, et al. Among authors: henderson ic. J Clin Oncol. 2005 Apr 1;23(10):2191-200. doi: 10.1200/JCO.2005.10.202. Epub 2005 Mar 14. J Clin Oncol. 2005. PMID: 15767638 Clinical Trial.
Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.
Parnes HL, Cirrincione C, Aisner J, Berry DA, Allen SL, Abrams J, Chuang E, Cooper MR, Perry MC, Duggan DB, Szatrowski TP, Henderson IC, Norton L; Cancer and Leukemia Group B. Parnes HL, et al. Among authors: henderson ic. J Clin Oncol. 2003 May 1;21(9):1819-24. doi: 10.1200/JCO.2003.05.119. J Clin Oncol. 2003. PMID: 12721259 Clinical Trial.
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944).
Kimmick GG, Cirrincione C, Duggan DB, Bhalla K, Robert N, Berry D, Norton L, Lemke S, Henderson IC, Hudis C, Winer E; Cancer and Leukemia Group B. Kimmick GG, et al. Among authors: henderson ic. Breast Cancer Res Treat. 2009 Feb;113(3):479-90. doi: 10.1007/s10549-008-9943-2. Epub 2008 Feb 28. Breast Cancer Res Treat. 2009. PMID: 18306034 Free PMC article. Clinical Trial.
181 results